BamSEC and AlphaSense Join Forces
Learn More

Oruka Therapeutics Inc.

NASDAQ: ORKA    
Share price (12/20/24): $20.31    
Market cap (12/20/24): $711 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 20 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 10 pages Amended and Restated Employment Letter Agreement by and Between the Company and Arjun Agarwal, Dated as of October 3, 2024
12/34/56
EX-10.1
from 8-K 10 pages Amended and Restated Employment Letter Agreement by and Between the Company and Dr. Lawrence Klein, Dated as of October 3, 2024
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 64 pages Securities Purchase Agreement
12/34/56
EX-10.25
from 8-K 10 pages Consulting Agreement
12/34/56
EX-10.16
from 8-K 7 pages Employee Warrant Agreement
12/34/56
EX-10.13
from 8-K 2 pages Second Amendment to the Oruka Therapeutics, Inc. Amended and Restated 2024 Equity Incentive Plan
12/34/56
EX-10.11
from 8-K 9 pages Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan
12/34/56
EX-10.10
from 8-K 14 pages Oruka Therapeutics, Inc. 2024 Stock Incentive Plan
12/34/56
EX-10.1
from 425 9 pages Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 9 pages Asset Purchase Agreement
12/34/56
EX-10.2
from 8-K 31 pages Amended and Restated Subscription Agreement
12/34/56
EX-10.2
from 425 31 pages Amended and Restated Subscription Agreement
12/34/56
EX-10.1
from 425 3 pages Oruka Therapeutics, Inc. 221 Crescent Street, Building 23, Suite 105 Waltham, Ma 02453 Attention: Lawrence Klein Email: [***] Re: Subscription Agreement – Purchase Price to Whom It May Concern
12/34/56
EX-10.1
from 8-K 3 pages Oruka Therapeutics, Inc. 221 Crescent Street, Building 23, Suite 105 Waltham, Ma 02453 Attention: Lawrence Klein Email: [***] Re: Subscription Agreement – Purchase Price to Whom It May Concern
12/34/56
EX-10.51
from S-4/A 27 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amended and Restated Antibody Discovery and Option Agreement
12/34/56
EX-10.50
from S-4/A 28 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Amended and Restated Antibody Discovery and Option Agreement
12/34/56
EX-10.49
from S-4 10 pages Amended and Restated Employment Offer Letter, Dated April 12, 2024, by and Between Oruka Therapeutics, Inc. and Paul Quinlan
12/34/56
EX-10.48
from S-4 10 pages Amended and Restated Employment Offer Letter, Dated March 15, 2024, by and Between Oruka Therapeutics, Inc. and Joana Goncalves
12/34/56